These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 18781517)

  • 1. Statistical issues in the experimental design and analysis of nonclinical data on the important topics of pharmacogenomics, pharmacology/toxicology (pharm/tox), and chemistry manufacturing and control.
    Chen JJ; Lin KK; Tsong Y
    J Biopharm Stat; 2008; 18(5):805-7. PubMed ID: 18781517
    [No Abstract]   [Full Text] [Related]  

  • 2. Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group.
    Bromley CM; Close S; Cohen N; Favis R; Fijal B; Gheyas F; Liu W; Lopez-Correa C; Prokop A; Singer JB; Snapir A; Tchelet A; Wang D; Goldstaub D;
    Pharmacogenomics J; 2009 Feb; 9(1):14-22. PubMed ID: 18794908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Workgroup report: Review of genomics data based on experience with mock submissions--view of the CDER Pharmacology Toxicology Nonclinical Pharmacogenomics Subcommittee.
    Leighton JK; Brown P; Ellis A; Harlow P; Harrouk W; Pine PS; Robison T; Rosario L; Thompson K
    Environ Health Perspect; 2006 Apr; 114(4):573-8. PubMed ID: 16581548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress report on the guidance for industry for statistical aspects of the design, analysis, and interpretation of chronic rodent carcinogenicity studies of pharmaceuticals.
    Lin KK
    J Biopharm Stat; 2000 Nov; 10(4):481-501. PubMed ID: 11104389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of pharmacogenomics for drug development.
    Kirk RJ; Hung JL; Horner SR; Perez JT
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of single-nucleotide polymorphism maps in pharmacogenomics.
    McCarthy JJ; Hilfiker R
    Nat Biotechnol; 2000 May; 18(5):505-8. PubMed ID: 10802616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI.
    Wang SJ
    Pharm Stat; 2007; 6(4):283-96. PubMed ID: 17957727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Data completeness--the Achilles heel of drug-target networks.
    Mestres J; Gregori-Puigjané E; Valverde S; Solé RV
    Nat Biotechnol; 2008 Sep; 26(9):983-4. PubMed ID: 18779805
    [No Abstract]   [Full Text] [Related]  

  • 9. Statistical issues in gene association studies.
    Watanabe RM
    Methods Mol Biol; 2011; 700():17-36. PubMed ID: 21204024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current regulatory toxicology perspectives on the development of herbal medicines to prescription drug products in the United States.
    Wu KM; Ghantous H; Birnkrant DB
    Food Chem Toxicol; 2008 Aug; 46(8):2606-10. PubMed ID: 18614266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological and toxicological principles of research on drugs in man].
    Gross F
    Arzneimittelforschung; 1973 Nov; 23(11):Suppl:1619-25. PubMed ID: 4205542
    [No Abstract]   [Full Text] [Related]  

  • 12. Statistics in pharmacology.
    Spina D
    Br J Pharmacol; 2007 Oct; 152(3):291-3. PubMed ID: 17618311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory perspectives of Type II prodrug development and time-dependent toxicity management: nonclinical Pharm/Tox analysis and the role of comparative toxicology.
    Wu KM; Farrelly JG
    Toxicology; 2007 Jul; 236(1-2):1-6. PubMed ID: 17507137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic considerations in the design of toxicology experiments.
    Darby TD
    Clin Toxicol; 1978 Feb; 12(2):229-38. PubMed ID: 648118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive design: a concept whose time has come.
    Jones B
    Pharm Stat; 2006; 5(2):83-4. PubMed ID: 17080764
    [No Abstract]   [Full Text] [Related]  

  • 17. [Trends in the post-genomic pharmacological research].
    Wei EQ; Shen JZ
    Sheng Li Ke Xue Jin Zhan; 2002 Jan; 33(1):7-11. PubMed ID: 12001739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genset-Abbott deal heralds pharmacogenomics era.
    Marshall A
    Nat Biotechnol; 1997 Sep; 15(9):829-30. PubMed ID: 9306389
    [No Abstract]   [Full Text] [Related]  

  • 19. Guidelines for evaluation of drugs for use in man. Report of a WHO scientific group.
    World Health Organ Tech Rep Ser; 1975; (563):1-59. PubMed ID: 803745
    [No Abstract]   [Full Text] [Related]  

  • 20. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.